Microbot Medical (MBOT) 10-K 2 Apr 18 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2017	Mar. 30, 2018	Jun. 30, 2017
Document And Entity Information
Entity Registrant Name	Microbot Medical Inc.
Entity Central Index Key	883,975
Document Type	10-K
Document Period End Date	Dec. 31, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity's Reporting Status Current	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 40,850,000
Entity Common Stock, Shares Outstanding		42,120,427
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,017

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands		Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents		$ 10,787	$ 2,709
Restricted cash		27
Other current assets		116	606
Total current assets		10,930	3,315
Fixed assets, net		90	53
Total assets		11,020	3,368
Current liabilities:
Trade payables		78	512
Accrued liabilities		450	271
Total current liabilities		528	783
Long-term liabilities:
Convertible notes			76
Derivative warrant liability		28	313
Total long term liabilities		28	389
Total liabilities		556	1,172
Commitments and contingencies
Temporary equity:
Common stock of $0.01 par value; issued and outstanding: 10,702,838 shares as of December 31, 2017 and 2016		500	500
Shareholders’ equity:
Preferred stock of $0.01 par value; Authorized: 1,000,000 shares as of December 31, 2017 and 2016; issued and outstanding: 4,001 and 9,736 shares as of December 31, 2017 and 2016, respectively	[1]
Common stock of $0.01 par value; Authorized: 220,000,000 as of December 31, 2017 and 2016; issued and outstanding: 29,880,289 and 15,848,136 shares as of December 31, 2017, and December 31, 2016, respectively		406	266
Additional paid-in capital		30,182	14,465
Accumulated deficit		(20,624)	(13,035)
Total shareholders’ equity		9,964	1,696
Total liabilities and shareholders’ equity		$ 11,020	$ 3,368
[1]	Less than 1

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Temporary equity, par value	$ 0.01	$ 0.01
Temporary equity, shares issued	10,702,838	10,702,838
Temporary equity, shares outstanding	10,702,838	10,702,838
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	4,001	9,736
Preferred stock, shares outstanding	4,001	9,736
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	220,000,000	220,000,000
Common stock, shares issued	29,880,289	15,848,136
Common stock, shares outstanding	29,880,289	15,848,136

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Statement [Abstract]
Research and development expenses, net	$ 1,100	$ 901
General and administrative expenses	4,167	8,734
Operating loss	(5,267)	(9,635)
Financing expenses, net	2,322	28
Net loss	$ (7,589)	$ (9,663)
Net loss per share, basic and diluted	$ 0.18	$ 0.4
Weighted-average number of common shares outstanding, basic and diluted	32,682,401	14,293,737

Consolidated Statements of Shar

Consolidated Statements of Shareholder’s Equity - USD ($) $ in Thousands	Preferred A Shares Microbot Medical Ltd. Pre-Merger [Member]	[1]	Preferred A Shares Microbot Medical Inc. Post-Merger [Member]	[1]	Common Stock [Member]		Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total		Temporary Equity [Member]
Balance at Dec. 31, 2015	$ 87				$ 132		$ 3,089	$ (3,372)	$ (64)
Balance, shares at Dec. 31, 2015	8,708,132				13,182,660
Conversion of convertible notes and exercise of warrants issued upon conversion	$ 48						1,803		1,851
Conversion of convertible notes and exercise of warrants issued upon conversion, shares	4,746,237
Effect of reverse recapitalization	$ (135)				$ 153		454		472
Effect of reverse recapitalization, shares	(13,454,369)				15,301,675
Common stock classified as temporary equity							(500)		(500)		500
Beneficial Conversion Feature recorded on convertible debt acquired in reverse recapitalization							2,029		2,029
Transaction costs incurred in reverse recapitalization					$ 78		6,817		6,895
Transaction costs incurred in reverse recapitalization, shares					7,802,639
Cancellation of ordinary shares and issuance of preferred shares				[2]	$ (97)		97
Cancellation of ordinary shares and issuance of preferred shares, shares			9,736		(9,736,000)
Share based compensation							676		$ 676
Exercise of options, shares
Net loss								(9,663)	$ (9,663)
Balance at Dec. 31, 2016				[2]	$ 266		14,465	(13,035)	1,696		500
Balance, shares at Dec. 31, 2016			9,736		26,550,974	[3]
Share based compensation					$ 1		478		479
Share based compensation, shares					120,000
Issuance of common stock					$ 45		12,657		12,702
Issuance of common stock, shares					4,450,000
Exercise of options					$ 4		(4)
Exercise of options, shares					471,794				(471,794)
Cashless exercise of warrants						[2]				[2]
Cashless exercise of warrants, shares					359
Extinguishment of convertible notes and issuance of preferred A shares				[2]			2,676		2,676
Extinguishment of convertible notes and issuance of preferred A shares, shares			3,255
Conversion of preferred A shares to common stock				[2]	$ 90		(90)
Conversion of preferred A shares to common stock, shares			(8,990)		8,990,000
Net loss								(7,589)	(7,589)
Balance at Dec. 31, 2017				[2]	$ 406		$ 30,182	$ (20,624)	$ 9,964		$ 500
Balance, shares at Dec. 31, 2017			4,001		40,583,127	[3]
[1]	Share data for periods prior to the reverse recapitalization represents the legal equity structure of Microbot Medical Ltd. with the number of shares adjusted to retroactively reflect the one-to-nine Reverse Stock Split effected on November 28, 2016 as well as the reverse recapitalization consummated on November 28, 2016.
[2]	Less than 1
[3]	Includes 10,702,838 common stock classified as temporary equity.

Consolidated Statements of Sha6

Consolidated Statements of Shareholder’s Equity (Parenthetical) - $ / shares	Nov. 28, 2016	Dec. 31, 2017	Dec. 31, 2016
Statement of Stockholders' Equity [Abstract]
Per share		$ 0.01	$ 0.01
Reverse stock split	one-to-nine Reverse Stock Split
Temporary equity		10,702,838	10,702,838

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017		Dec. 31, 2016	Nov. 28, 2016
OPERATING ACTIVITIES
Net loss	$ (7,589)		$ (9,663)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	21		10
Interest and amortization of discount on convertible notes	237		333
Share-based transaction costs incurred in reverse recapitalization			7,258
Financing loss on debt extinguishment	2,364
Changes in fair value of derivative warrant liability	(285)		(262)
Share-based compensation expense	479		676
Changes in assets and liabilities:
Other receivables	(14)		538
Other payables and accrued liabilities	(69)		324
Net cash used in operating activities	(4,856)		(786)
INVESTMENT ACTIVITIES
Increase in restricted cash	(27)
Purchase of property and equipment	(58)		(25)
Net cash used in investing activities	(85)		(25)
FINANCING ACTIVITIES
Acquisition of a subsidiary in connection with reverse recapitalization			269
Transaction costs incurred in reverse recapitalization			(347)
Inflows in connection with current assets and liabilities acquired in reverse recapitalization, net	317		2,002
Exercise of warrants issued upon conversion of notes			409
Issuance of common stock, net of issuance costs	12,702
Issuance of convertible notes			750
Net cash provided by financing activities	13,019		3,083
Increase in cash and cash equivalents	8,078		2,272
Cash and cash equivalents at the beginning of the year	2,709		437
Cash and cash equivalents at the end of the year	10,787		2,709
Non-cash financing transactions:
Cashless exercise of warrants		[1]
Conversion of preferred A shares into common shares	90
Extinguishment of convertible notes in exchange for preferred A shares	$ 2,083	[1]
Assets acquired (liabilities assumed):
Current assets excluding cash and cash equivalents				$ (3,618)
Current liabilities				811
Derivative warrant liability				575
Convertible note				2,029
Reverse recapitalization effect on equity				472
Cash acquired in connection with reverse recapitalization				$ 269
[1]	Less than 1

General

General	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
General	NOTE 1 - GENERAL A. Description of Business Microbot Medical Inc. (the “Company”) is a pre-clinical medical device company specializing in the research, design and development of next generation micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The Company is primarily focused on leveraging its micro-robotic technologies with the goal of improving surgical outcomes for patients. It was incorporated on August 2, 1988 in the State of Delaware under the name Cellular Transplants, Inc. The original Certificate of Incorporation was restated on February 14, 1992 to change the name of the Company to Cyto Therapeutics, Inc. On May 24, 2000, the Certificate of Incorporation as restated was further amended to change the name of the Company to StemCells, Inc. On November 28, 2016, the Company consummated a transaction pursuant to an Agreement and Plan of Merger, dated August 15, 2016, with Microbot Medical Ltd., a private medical device company organized under the laws of the State of Israel (“Microbot Israel”), and C&RD Israel Ltd. (“Merger Sub”), an Israeli corporation and wholly-owned subsidiary of the Company, whereby Merger Sub merged with and into Microbot Israel and Microbot Israel surviving as a wholly-owned subsidiary of the Company (the “Merger”). Pursuant to the terms of the Merger, at the effective time of the Merger, each outstanding ordinary share of Microbot Israel capital stock was converted into the right to receive approximately 2.9 shares of the Company’s common stock, par value $0.01 per share, after giving effect to a one for nine reverse stock split (the “Reverse Stock Split”), for an aggregate of 26,550,974 shares of Company’s common Stock issued to the former Microbot Israel shareholders. In addition, all outstanding options to purchase the ordinary shares of Microbot Israel were assumed by the Company and converted into options to purchase an aggregate of 2,614,916 shares of the Company’s common stock. Additionally, the Company issued an aggregate of 7,802,639 restricted shares of its common stock or rights to receive the Company’s common stock, to certain advisers. On the same day and in connection with the Merger, the Company changed its name from StemCells, Inc. to Microbot Medical Inc. On November 29, 2016, the Company’s common stock began trading on the Nasdaq Capital Market under the symbol “MBOT”. As a result of the Merger, Microbot Israel became a wholly owned subsidiary of the Company. The transaction between the Company and Microbot Israel was accounted for as a reverse recapitalization. As the shareholders of Microbot Israel received the largest ownership interest in the Company, Microbot Israel was determined to be the “accounting acquirer” in the reverse recapitalization. As a result, the historical financial statements of the Company were replaced with the historical financial statements of Microbot Israel. Unless indicated otherwise, pre-acquisition share, options and warrants data included in these financial statements is retroactively adjusted to reflect the Reverse Stock Split and the Merger. Prior to the Merger, the Company was a biopharmaceutical company that conducts research, development, and commercialization of stem cell therapeutics and related technologies. Substantially the sale of all material assets relating to the stem cell business were completed on November 29, 2016. The Company and its subsidiaries are collectively referred to as the “Company”. “StemCells” or “StemCells, Inc.” refers to the Company prior to the Merger. B. Risk Factors To date, the Company has not generated revenues from its operations. As of the date of issuance of these financial statements, the Company has cash and cash equivalent balance of approximately $9.5 million, which management believes is sufficient to fund its operations for more than 12 months from the date of issuance of these financial statements and sufficient to fund its operations necessary to continue development activities of its current proposed products. Due to continuing research and development activities, the Company expects to continue to incur net losses into the foreseeable future. The Company plans to continue to fund its current operations as well as other development activities relating to additional product candidates, through future issuances of either debt and/or equity securities and possibly additional grants from the Israeli Innovation Authority. The Company’s ability to raise additional capital in the equity and debt markets is dependent on a number of factors, including, but not limited to, the market demand for the Company’s stock, which itself is subject to a number of development and business risks and uncertainties, as well as the uncertainty that the Company would be able to raise such additional capital at a price or on terms that are favorable to the Company. C. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions pertaining to transactions and matters whose ultimate effect on the financial statements cannot precisely be determined at the time of financial statements preparation. Although these estimates are based on management’s best judgment, actual results may differ from these estimates.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The significant accounting policies applied in the preparation of the financial statements are as follows: A. Basis of Presentation The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”). B. Financial Statement in U.S. Dollars The functional currency of the Company is the U.S. dollar (“dollar”) since the dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future. Transactions and balances denominated in dollars are presented at their original amounts. Transactions and balances denominated in foreign currencies have been re-measured to dollars in accordance with the provisions of ASC 830-10, “Foreign Currency Translation”. All transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the statement of operations as financial income or expenses, as appropriate. C. Cash and Cash Equivalents Cash and cash equivalents consist of cash and demand deposits in banks, and other short-term liquid investments (primarily interest-bearing time deposits) with original maturities of less than three months. D. Fair Value of Financial Instruments The carrying values of cash and cash equivalents, other receivable and other accounts payable and accrued liabilities approximate their fair value due to the short-term maturity of these instruments. The Company measures the fair value of certain of its financial instruments (such as the derivative warrant liabilities) on a recurring basis. The method of determining the fair value of derivative warrant liabilities is discussed in Note 7. A fair value hierarchy is used to rank the quality and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value will be classified and disclosed in one of the following three categories: ● Level 1 ● Level 2 ● Level 3 E. Fixed Assets Fixed assets are presented at costs less accumulated depreciation. Depreciation is calculated based on the straight-line method over the estimated useful lives of the assets, as the following annual rates: % Research equipment and software 25-33 Furniture and office equipment 7 F. Liabilities Due to Termination of Employment Agreements Under Israeli employment laws, employees of Microbot Israel are included under Article 14 of the Severance Compensation Act, 1963 (“Article 14”). According to Article 14, these employees are entitled to monthly deposits made by Microbot Israel on their behalf with insurance companies. Payments in accordance with Article 14 release Microbot Israel from any future severance payments (under the Israeli Severance Compensation Act, 1963) with respect of those employees. The aforementioned deposits are not recorded as an asset in the Company’s balance sheet. G. Basic and Diluted Net Loss Per Share Basic net loss per share is computed by dividing net loss, as adjusted to include the weighted average number of common shares outstanding during the year. Common shares and preferred shares contingently issuable for little or no cash are included in basic net loss per share on an as issued basis. Diluted net loss per share is computed by dividing net loss, as adjusted to include preferred shares dividend participation rights of preferred shares outstanding during the year as well as of preferred shares that would have been outstanding if all potentially dilutive preferred shares had been issued, by the weighted average number of common shares outstanding during the year, plus the number of common shares that would have been outstanding if all potentially dilutive common shares had been issued, using the treasury stock method, in accordance with ASC 260-10 “Earnings per Share”. All outstanding stock options and warrants have been excluded from the calculation of the diluted loss per share for the years ended December 31, 2017 and December 31, 2016, since all such securities have an anti-dilutive effect. The weighted average number of shares outstanding has been retroactively restated for the equivalent number of shares received by the accounting acquirer as a result of the reverse recapitalization as if these shares had been outstanding as of the beginning of the earliest period presented. H. Research and Development Expenses, Net Research and development expenses are charged to the statement of operations as incurred. Grants for funding of approved research and development projects are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred and applied as a deduction from the research and development expenses. I. Convertible Notes Proceeds from the sale of debt securities with a conversion feature are allocated to equity based on the intrinsic value of such conversion feature in accordance with ASC 470-20 “Debt with Conversion and Other Options”, with a corresponding discount on the debt instrument recorded in liabilities which is amortized in finance expense over the term of the notes. Convertible notes with characteristics of both liabilities and equity are classified as either debt or equity based on the characteristics of its monetary value, with convertible notes classified as debt being measured at fair value, in accordance with ASC 480-10, “Accounting for Certain Financial instruments with Characteristics of both Liabilities and Equity”. J. Share-Based Compensation The Company applies ASC 718-10, “Share-Based Payment,” which requires the measurement and recognition of compensation expenses for all share-based payment awards made to employees and directors including stock options under the Company’s stock plans based on estimated fair values. ASC 718-10 requires companies to estimate the fair value of stock options using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company’s statement of operations. The Company accounts for stock-based compensation awards to non-employees in accordance with FASB ASC 505-50, “Equity-Based Payments to Non-Employees” (“FASB ASC 505-50”). Under FASB ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The Company estimates the fair value of stock options granted as share-based payment awards using a Black-Scholes options pricing model. The option-pricing model requires a number of assumptions, of which the most significant are expected volatility and the expected option term (the time from the grant date until the options are exercised or expire). Expected volatility is estimated based on volatility of similar companies in the technology sector for equity awards granted prior to the Merger and on the Company’s trading share price for equity awards granted subsequent to the Merger. The Company has historically not paid dividends and has no foreseeable plans to issue dividends. The risk-free interest rate is based on the yield from governmental zero-coupon bonds with an equivalent term. The expected stock option term is calculated for stock options granted to employees and directors using the “simplified” method. Grants to non-employees are based on the contractual term. Changes in the determination of each of the inputs can affect the fair value of the stock options granted and the results of operations of the Company. K. Reclassification Certain prior year amounts have been reclassified to conform to the current year presentation. L. Transaction Costs Transaction costs incurred in the Merger were charged directly to equity to the extent of cash and net other current assets acquired. Transaction costs in excess of cash acquired were charged to general and administrative expenses. M. Income Taxes The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of December 31, 2017 and 2016, the Company had a full valuation allowance against deferred tax assets. N. Recent Accounting Standards In May 2014, the FASB issued ASU 2014-09 “Revenue from Contracts with Customers” to provide a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. The ASU supersedes most current revenue recognition guidance, including industry-specific guidance. The FASB subsequently issued ASU 2015-14, ASU 2016-08 and ASU 2016-12, which clarified the guidance, provided scope improvements and amended the effective date of ASU 2014-09. As a result, ASU 2014-09 becomes effective for the Company in the first quarter of 2018, with early adoption permitted. The Company has not yet generated revenues to date, and does not yet know the impact the standard may have on its consolidated financial statements. In February 2016, the FASB issued ASU 2016-02 “Leases” to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. For operating leases, the ASU requires a lessee to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments, on its balance sheet. The ASU retains the current accounting for lessors and does not make significant changes to the recognition, measurement, and presentation of expenses and cash flows by a lessee. This ASU is effective for the Company in the first quarter of 2019, with early adoption permitted. The Company continues to evaluate the effect of the adoption of this ASU and expects the adoption will result in an increase in the assets and liabilities on the consolidated balance sheets for operating leases (refer to Note 8) and will likely have an insignificant impact on the consolidated statements of comprehensive loss. In June 2016, the FASB issued ASU 2016-13 “Financial Instruments – Credit Losses” to improve information on credit losses for financial assets and net investment in leases that are not accounted for at fair value through net income. The ASU replaces the current incurred loss impairment methodology with a methodology that reflects expected credit losses. This ASU is effective for the Company in the first quarter of 2020, with early adoption permitted. The Company is currently evaluating the effect the adoption of this ASU will have on its consolidated financial statements. In November 2016, the FASB issued ASU 2016-18 “Restricted Cash” to provide guidance on the presentation of restricted cash in the statement of cash flows. Currently, the statement of cash flows explained the change in cash and cash equivalents for the period. The ASU requires that the statement of cash flows explain the change in cash, cash equivalents and restricted cash for the period. The ASU is effective for the Company in the first quarter of 2018, with early adoption permitted. The Company does not expect the adoption to have a material effect on the statements of cash flows as the Company’s restricted cash is not expected to be material. In May 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-09, “Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting,” which clarifies when a change to terms or conditions of a share-based payment award must be accounted for as a modification. The new guidance requires modification accounting if the vesting condition, fair value or the award classification is not the same both before and after a change to the terms and conditions of the award. The new guidance is effective for the Company on a prospective basis beginning on January 1, 2018 and early adoption is permitted. The Company does not expect to change terms or conditions of share-based payment awards, and therefore, does not expect the adoption of this standard to have a material impact on its consolidated financial statements. In July 2017, the FASB issued ASU 2017-11, which includes Part I “Accounting for Certain Financial Instruments with Down Round Features” and Part II “Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-Controlling Interests with a Scope Exception”. The ASU makes limited changes to the Board’s guidance on classifying certain financial instruments as either liabilities or equity. The ASU’s objective is to improve (1) the accounting for instruments with “down-round” provisions and (2) the readability of the guidance in ASC 480 on distinguishing liabilities from equity by replacing the indefinite deferral of certain pending content with scope exceptions. The ASU is effective for the Company in the first quarter of 2019, with early adoption permitted. The Company has derivative warranty liabilities as discussed in Note 7 which upon adoption of the new standard are expected to be classified as equity.

Other Current Assets

Other Current Assets	12 Months Ended
	Dec. 31, 2017
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other Current Assets	NOTE 3 - OTHER CURRENT ASSETS As of December 31, 2017 2016 Deposit in escrow account (*) $ - $ 400 Government institutions 35 15 Prepaid expenses and others 81 191 $ 116 $ 606 (*) Purchase Agreement with BOCO Pursuant to the terms and subject to the conditions set forth in the Asset Purchase Agreement, the Sellers sold to BOCO US certain stem and progenitor cell lines that have been researched, studied or manufactured by the Company since 2007 (the “Cell Lines”) and certain other tangible and intangible assets, including intellectual property and books and records, related to the foregoing (together with the Cell Lines, the “Assets”) in exchange for $4 million in cash (the “Asset Consideration”). Of the Asset Consideration, $300 was provided to the Company prior to November 11, 2016 in exchange for the Sellers’ agreement not to solicit or reach any agreement with any third party pertaining to the sale of the Assets, and $400 will remain in a twelve-month escrow for the benefit of BOCO US to satisfy certain indemnification obligations of the Sellers which may arise and which, subject to any valid indemnification claims of BOCO US, will be released to the Company at the end of such 12-month period. In addition, sixteen former employees of the Company received, in the aggregate, $495 in accordance with their June 2016 agreements with the Company under which each accepted a more than 50% reduction in his or her severance award otherwise payable. The Asset Purchase Agreement contains certain covenants prohibiting the Sellers from, during the four-year period immediately following the completion of the Asset Sale, (a) engaging in or having certain financial interests in a business that is engaged in the research, development or commercialization of the Cell Lines, or (b) soliciting for employment employees of BOCO US. On November 29, 2016, the Sellers completed the sale of the Assets. As of December 31, 2017, the Company received $320 from the escrow account and paid $80 to certain consultant relating to BOCO transaction. The opening balance sheet as of the Merger date included a receivable balance with respect to sale of the Assets of $3.5 which was collected in full as of December 31 2017.

Fixed Assets, Net

Fixed Assets, Net	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Fixed Assets, Net	NOTE 4 - FIXED ASSETS, NET As of December 31, 2017 2016 Cost: Research equipment and software $ 76 $ 54 Furniture and office equipment 92 56 168 110 Accumulated Depreciation: Research equipment and software 42 29 Furniture and office equipment 36 28 78 57 $ 90 $ 53

Accrued Liabilities

Accrued Liabilities	12 Months Ended
	Dec. 31, 2017
Payables and Accruals [Abstract]
Accrued Liabilities	NOTE 5 - ACCRUED LIABILITIES As of December 31, 2017 2016 Employees $ 64 $ 102 Government institution 56 24 Other current liabilities 330 145 $ 450 $ 271

Convertible Loan from Sharehold

Convertible Loan from Shareholders	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Convertible Loan from Shareholders	NOTE 6 - CONVERTIBLE LOAN FROM SHAREHOLDERS Microbot Israel Convertible Loan Agreements On October 8, 2015, Microbot Israel entered into a convertible loan agreement with several investors who were also existing shareholders. According to the loan agreement, Microbot Israel received an amount of $419. The loan bore interest of 10% and was converted to both equity shares and preferred shares warrants of Microbot Israel on the nine-month anniversary of the loan. The Company concluded the conversion feature is not a Beneficial Conversion Feature pursuant to the provisions of ASC 470-20, “Debt with Conversion and Other Options”. Accordingly, the proceeds were recorded in liabilities in their entirety at the date of issuance. On July 7, 2016, the outstanding principal and accrued interest were converted into 1,315,023 Series A preferred shares, of Microbot Israel (the “Series A Preferred Shares”) and 1,188,275 warrants to purchase the Series A Preferred Shares, at an exercise price of $1.00 per share. The preferred shares warrants were exercised in full in September 2016 for total gross proceeds to Microbot Israel of $410. On May 11, 2016, Microbot Israel entered into a convertible loan agreement with several investors who were also existing shareholders. The loan bore interest at a fixed rate of 10% per annum beginning on the issuance date. At maturity, all of the outstanding principal and accrued interest was converted into Microbot Israel’s ordinary shares subject to the conversion or default events specified in the loan agreement, based on a conversion price that represents a 20% discount on Microbot Israel’s valuation upon such default events. On November 28, 2016, upon the consummation of the Merger, the loan was converted into an aggregate of 2,242,939 shares of Company’s common stock. The Company concluded the value of the loan is predominantly based on a fixed monetary amount known at the date of issuance as represented by the 20% discount on the Company’s valuation. Accordingly, the loan was classified as debt and was measured at its fair value, pursuant to the provisions of ASC 480-10, “Accounting for Certain Financial instruments with Characteristics of both Liabilities and Equity”. The fair value of the loan was measured based on observable inputs as the fixed monetary value of the variable number of shares to be issued upon conversion (level 2 measurement). Secured Note to Alpha Capital Anstalt On August 15, 2016, concurrent with the execution of the Agreement and Plan of Merger (see Note 1A), StemCells Inc. issued a 6.0% secured note (the “Note”) to Alpha Capital Anstalt (“Alpha Capital”), in the principal amount of $2,000, for value received, payable upon the earlier of (i) 30 days following the consummation of the Merger and (ii) December 31, 2016. Proceeds from the Note were used for the payment of costs and expenses in connection with the Merger and operational expenses leading to such Closing. The Note bears interest at 6% per annum, payable monthly in arrears on the first of the month, beginning on January 1, 2017 until the principal amount is paid in full. In addition, the Note is secured by a first priority security interest in all of the Company’s intellectual property and certain other general assets pursuant to a Security Agreement Securities Exchange Agreement with Alpha Capital As of the effective time of the Merger, the Company entered into a Securities Exchange Agreement (the “Exchange Agreement”) with Alpha Capital, providing for the issuance to Alpha Capital of a convertible promissory note by the Company (the “Convertible Note”) in a principal amount of $2,029, which is equal to the principal and accrued interest under the Note, in exchange for (a) the full satisfaction, termination and cancellation of the Note and (b) the release and termination of the Security Agreement and the first priority security interest granted thereunder. The Convertible Note was convertible into the Company’s Common Stock any time after November 28, 2017 and until the maturity date of November 28, 2019, based on a conversion price of $0.64, subject to adjustments as provided in the Exchange Agreement. Pursuant to the terms of the Convertible Note, the Company was obligated to pay interest on the outstanding principal amount owed under the Convertible Note at a fixed rate per annum of 6.0%, payable at maturity or earlier upon conversion. The Exchange Agreement contains customary representations and warranties and usual and customary affirmative and negative covenants. The Convertible Note also contained certain customary events of default. As the Exchange Agreement represented the consummation of the original intent of the Company and Alpha Capital, as of the date of execution of the Merger Agreement (August 2016), to enter into a $2 million convertible note sale transaction, upon the consummation of the Merger, the Company accounted for the convertible note in accordance with such economic substance, as if it had been issued for a cash consideration equal to the principal and accrued interest on the Note, as of the effective date of the Merger, in the amount of $2,029 (the “Assumed Consideration”), which is equal to the principal amount of the Convertible Note as determined in the Exchange Agreement. The Company concluded the conversion feature of the Convertible Note, based on the commitment date of November 28 2016 (the Exchange Agreement date), is a Beneficial Conversion Feature pursuant to the provisions of ASC 470-20, “Debt with Conversion and Other Options”. Accordingly, $2,029 of the Assumed Consideration was recorded in equity with a corresponding discount on the Convertible Note, to be amortized over its term through maturity. See also Note 9 – Securities Exchange Agreements with Alpha Capital. The carrying value of the Convertible Note as of the periods below was calculated as follow: As of December 31, 2017 2016 Convertible note $ - $ 2,029 Unamortized discount - (1,963 ) Accrued interest - 10 $ - $ 76

Derivative Warrant Liabilities

Derivative Warrant Liabilities	12 Months Ended
	Dec. 31, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Warrant Liabilities	NOTE 7 - DERIVATIVE WARRANT LIABILITIES As part of StemCell’s obligations under the Merger Agreement, in August 2016, StemCells negotiated with certain institutional holders of its 2016 Series A and Series B Warrants, issued by prior to the Merger, to have such holders surrender their 2016 Series B Warrants in exchange for a reduced exercise price of $0.30 per share on their existing 2016 Series A Warrants and the elimination of the anti-dilution price protection in the 2016 Series A Warrants. As a result, the exercise price for all outstanding 2011 Series A Warrants and 2016 Series A and Series B Warrants was reset to $0.30 per share. Subsequent to the reset of the exercise price, an aggregate of 531,814 (from an outstanding aggregate of 578,081) 2011 Series A Warrants were exercised. For the exercise of these warrants, the Company issued 531,814 shares of its common stock prior to the Merger. The remaining outstanding warrants and terms as of December 31, 2017 and 2016 is as follows: Issuance Date Outstanding as of December 31, 2016 Outstanding as of December 31, 2017 Exercise Price Exercisable as of December 31, 2017 Exercisable Through Series A (2011) 64,230 - $ 151.20 - December 2016 Series A (2013) 57,814 57,814 $ 194.40 57,814 October 2018 Series A (2013) 2,718 2,718 $ 183.60 2,718 April 2023 Series A (2015) 10,139 10,139 $ 91.80 10,139 April 2020 Series A (2016)(a) 10,047 9,279 $ 2.70 9,279 March 2018 Series B (2016)(a) 41,116 41,116 $ 2.70 41,116 March 2022 (a) These warrants contain a full ratchet anti-dilution price protection so that, in most situations upon the issuance of any common stock or securities convertible into common stock at a price below the then-existing exercise price of the outstanding warrants, the warrant exercise price will be reset to the lower common stock sales price. As such anti-dilution price protection does not meet the specific conditions for equity classification, the Company is required to classify the fair value of these warrants as a liability, with changes in fair value to be recorded as income (loss) due to change in fair value of warrant liability. The estimated fair value of our warrant liability at December 31, 2017 and December 31, 2016, was approximately $28 and $313, respectively. As quoted prices in active markets for identical or similar warrants are not available, the Company uses directly observable inputs in the valuation of its derivative warrant liabilities (level 2 measurement). The Company uses the Black-Scholes valuation model to estimate fair value of these warrants. In using this model, the Company makes certain assumptions about risk-free interest rates, dividend yields, volatility, expected term of the warrants and other assumptions. Risk-free interest rates are derived from the yield on U.S. Treasury debt securities. Dividend yields are based on our historical dividend payments, which have been zero to date. Volatility is estimated from the historical volatility of our common stock as traded on NASDAQ. The expected term of the warrants is based on the time to expiration of the warrants from the date of measurement. In March 2017, an institutional holder executed a cashless exercise of 768 warrants and 359 shares of Common Stock were issued in connection therewith. The following table summarizes the observable inputs used in the valuation of the derivative warrant liabilities as of December 31, 2017 and December 31, 2016 : Series A (2011) Series A (2013) Series A (2013) Series A (2015) Series A (2016) Series B (2016) Total Balances at December 31, 2016 $ - $ 12 $ 9 $ 22 $ 43 $ 227 $ 313 Exercised - - - - - - - Cancelled - - - - - - - Changes in fair value - (12 ) (9 ) (22 ) (43 ) (199 ) (285 ) Balances at December 31, 2017 $ - $ - $ - $ - $ (* ) $ 28 $ 28 (*) Less than 1 The following table summarizes the observable inputs used in the valuation of the derivative warrant liabilities as of December 31, 2017 and December 31, 2016: As of December 31, 2017 As of December 31, 2016 Series A (2016) Series B (2016) Series A (2016) Series B (2016) Share price $ 1.02 $ 1.02 $ 6.10 $ 6.10 Exercise price $ 2.70 $ 2.70 $ 2.70 $ 2.70 Expected volatility 60 % 119 % 380 % 380 % Risk-free interest 1.24 % 1.89 % 0.85 % 1.93 % Dividend yield — — — — Expected life of up to (years) 0.25 4.25 1.2 5.2 Activity in such liabilities measured on a recurring basis is as follows: Derivative warrant liabilities As of December 31, 2016 $ 313 Revaluation of warrants (285 ) Exercise warrants (* ) As of December 31, 2017 $ 28 (*) Less than 1 Derivative warrant liabilities As of November 30, 2016 $ 575 Revaluation of warrants (262 ) Exercise warrants (* ) As of December 31, 2016 $ 313 (*) Less than 1 In accordance with ASC-820-10-50-2(g), the Company has performed a sensitivity analysis of the derivative warrant liabilities of the Company which are classified as level 3 financial instruments. The Company recalculated the value of warrants by applying a +/- 5% changes to the input variables in the Black-Scholes model that vary overtime, namely, the volatility and the risk-free rate. A 5.0% decrease in volatility would decrease the value of the warrants to $27; a 5.0% increase in volatility would increase the value of the warrants to $29. A 5.0% decrease or increase in the risk-free rate would not have materially changed the value of the warrants; the value of the warrants is not strongly correlated with small changes in interest rates.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 8 - COMMITMENTS AND CONTINGENCIES Microbot Israel obtained from the Israeli Innovation Authority (“IIA”) grants for participation in research and development for the years 2013 through December 31, 2017 in the total amount of approximately $1,183 and, in return, Microbot Israel is obligated to pay royalties amounting to 3% of its future sales up to the amount of the grant. The grant is linked to the exchange rate of the dollar to the New Israeli Shekel and bears interest of Libor per annum. The repayment of the grants is contingent upon the successful completion of the Company’s research and development programs and generating sales. The Company has no obligation to repay these grants, if the project fails, is unsuccessful or aborted or if no sales are generated. The financial risk is assumed completely by the Government of Israel. The grants are received from the Government on a project-by-project basis. Microbot Israel signed an agreement with the Technion Research and Development Foundation (“TRDF”) in June 2012 by which TRDF transferred to Microbot Israel a global, exclusive, royalty-bearing license. As partial consideration for the license, Microbot Israel shall pay TRDF royalties on net sales (between 1.5%-3%) and on sublicense income as detailed in the agreement. Lease Agreements In June 2016, the Company entered into an office lease agreement, with a term ending on February 28, 2018. According to the lease agreement, the monthly office lease payment is approximately $3. In December 2016, the Company entered into a cars lease agreement, which will end on December 31, 2019. According to the lease agreement, the monthly car lease payment is approximately $2.5. In May 2017, the Company entered into an office lease agreement effective from February 1, 2018, with a term ending on December 31, 2020. According to the lease agreement, the monthly office lease payment is approximately $14. The Company also has future minimum payments related to maintenance expenses in accordance with the lease agreements. The Company has guarantees in the amount of approximately $55 with respect to this lease agreement. Compensation Liability The Company incurred compensation commitments of approximately $400 to a former executive that management estimates as remote that this amount will ever be paid out and therefore is not reflected in these consolidated financial statements. Contract Research Agreement On January 27, 2017, the Company entered into a Contract Research Agreement (the “Research Agreement”) with The Washington University (“Washington U.”), pursuant to which the parties will collaborate to determine the effectiveness of the Company’s self-cleaning shunt. The study in WU includes several phases. The first phase (initial research) was completed. The parties are in the final stage of planning the next phase, including the related various costs. Litigation The Company is named as the defendant in a lawsuit, captioned Sabby Healthcare Master Fund Ltd. and Sabby Volatility Warrant Master Fund Ltd., Plaintiffs, against Microbot Medical Inc., Defendant, pending in the Supreme Court of the State of New York, County of New York. The complaint alleges, among other things, that the Company breached multiple representations and warranties contained in the Securities Purchase Agreement (the “SPA”) related to the June 8, 2017 equity financing of the Company (the “Financing”), of which the Plaintiffs participated. The complaint seeks rescission of the SPA and return of the Plaintiffs’ $3,375 purchase price with respect to the Financing, and damages in an amount to be determined at trial, but alleged to exceed $1 million. The parties presently are engaged in discovery. Due to the early stage in the ligation process, management is unable to assess the likelihood of the claim and the amount of potential damages, if any, to be awarded. Management believes that the claims made against it are without merit and intends to vigorously defend itself against these claims. See Note 16 – Subsequent Events, below.

Share Capital

Share Capital	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Share Capital	NOTE 9 - SHARE CAPITAL Each share of the Series A Convertible Preferred Stock, par value $0.01 per share, issued by the Company in December 2016 and in May 2017 (the “Series A Convertible Preferred Stock”), is convertible, at the option of the holder, into 1,000 shares of Common Stock, and confer upon the holder dividend rights on an as converted basis. Exercise of Warrants On March 2017, an institutional holder exercised, in a cashless transaction, 768 warrants and 359 shares of Common Stock were issued in connection therewith. Share capital developments: The authorized capital stock consists of 221,000,000 shares of capital stock, which consists of 220,000,000 shares of Common Stock and 1,000,000 shares of undesignated preferred stock, par value $0.01 (the “Preferred Stock”). As of December 31, 2017, the Company had 40,583,127 shares of Common Stock issued and outstanding, and 4,001 shares of Series A Convertible Preferred Stock issued and outstanding. On November 28, 2016, the Company filed a Certificate of Amendment to its Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware to (i) effect the Reverse Stock Split, (ii) change its name from “StemCells, Inc.” to “Microbot Medical Inc.” and (iii) increase the number of authorized shares of the Common Stock from 200,000,000 to 220,000,000 shares (the “Certificate of Amendment”). As a result of the Reverse Stock Split, the number of issued and outstanding shares of the Common Stock immediately prior to the Reverse Stock Split were reduced into a smaller number of shares, such that every nine shares of the Common Stock held by a stockholder immediately prior to the Reverse Stock Split were combined and reclassified into one share of the Common Stock. Immediately following the Reverse Stock Split and the Merger, there were 36,254,240 shares of the Common Stock issued and outstanding, which included certain rights to receive shares of Common Stock or equivalent securities but excludes shares underlying outstanding stock options and warrants and the Convertible Note. On December 27, 2016, the Company exchanged 9,735,925 shares or rights to acquire shares of its Common Stock, for 9,736 shares of a newly designated class of Series A Convertible Preferred Stock. See “- Securities Exchange Agreement with Alpha Capital” below. See also Note 6 – Securities Exchange Agreement with Alpha Capital, above. On January 5, 2017, the Company entered into a definitive securities purchase agreement with an institutional investor (the “Purchaser”) for the purchase and sale of an aggregate of 700,000 shares of Common Stock in a registered direct offering for $5.00 per share or gross proceeds of $3,500. The Company paid the placement agent a fee of $210 plus reimbursement of out-of-pocket expenses, as well as other offering-related expenses. On June 5, 2017, the Company entered into a Securities Purchase Agreement with certain institutional investors (the “Investors”) providing for the issuance and sale by the Company to the Investors of an aggregate of 3,750,000 shares of Common Stock, at a purchase price per share of $2.70. The gross proceeds to the Company was $10,125,000 before deducting placement agent fees and offering expenses of $922. In 2017, the Company issued an aggregate of 8,990,000 shares of its Common Stock upon the conversion of an aggregate of 8,990 shares of its Series A Convertible Preferred Stock. Employee stock option grant: In September 2014, Microbot Israel’s board of directors approved a grant of 403,592 stock options (1,167,693 stock options as retroactively adjusted to reflect the Merger) to its CEO, through MEDX Venture Group LLC. Each option was exercisable into an ordinary share, at an exercise price of $0.8 ($0.28 as retroactively adjusted to reflect the Merger). The stock options were fully vested at the date of grant. On May 2, 2016, Microbot Israel’s board of directors approved a grant of 500,000 stock options (1,447,223 as retroactively adjusted to reflect the Merger) to certain of its employees and directors. Each stock option was exercisable into an ordinary share, NIS 0.001 par value, of Microbot Israel, at an exercise price equal to the ordinary share’s par value. The stock options were fully vested at the date of grant. As a result, the Company recognized compensation expenses in the amount of $675 included in general and administrative expenses. As the exercise price of the stock options is nominal, Microbot Ltd estimated the fair value of the options as equal to the Company’s share price of $1.35 ($0.47 as retroactively adjusted to reflect the Merger) at the date of grant. On September 12, 2017, the Company adopted the 2017 Equity Incentive Plan (the “Plan”), which Plan authorizes, among other things, the grant of options to purchase shares of Common Stock to directors, officers and employees of the Company and to other individuals. On September 14, 2017, the board of directors approved a grant of stock options to purchase an aggregate of up to 1,812,712 shares of Common Stock to Mr. Harel Gadot, the Company’s Chairman of the Board, President and CEO, at an exercise price per share of $1.05. The stock options vest over a period of 3-5 years as outlined in the option agreements. As a result, the Company recognized compensation expenses in the amount of $156 included in general and administrative expenses for the period ended December 31, 2017. On September 14, 2017, the board of directors approved a grant of stock options to purchase an aggregate of up to 1,087,627 shares of Common Stock to Mr. Hezi Himelfarb, the company’s General Manager, COO and a member of the Board, at an exercise price per share of $1.29. The grant was subject to the Israeli Tax Authority’s approval of the plan which occurred on October 14, 2017. In accordance with the option agreement, the options vest for period of 3 years starting from the grand date. As a result, the Company recognized compensation expenses in the amount of $92 included in general and administrative expenses for the period ended December 31, 2017. On December 6, 2017, the board of directors approved a grant of 190,475 stock options to purchase an aggregate of up to 190,475 shares of Common Stock to certain of its directors, at an exercise price per share of $1.05. The stock options vest over a period of 3 years as outlined in the option agreements. As a result, the Company recognized compensation expenses in the amount of $5 included in general and administrative expenses for the period ended December 31, 2017. On December 28, 2017, the board of directors approved a grant of 990,543 stock options to purchase an aggregate of up to 990,543 shares of Common Stock to certain of its employees, at an exercise price per share of $1.02. The stock options vest over a period of 3 years as outlined in the option agreements. As a result, the Company recognized compensation expenses in the amount of $1 included in general and administrative expenses for the period ended December 31, 2017. In November, 2017, certain employees and consultants exercised 471,794 options to 471,794 shares of common stock at exercise price of $0.001 per share. A summary of the Company’s option activity related to options to employees and directors, and related information is as follows: For the year ended December 31, 2017 Number of stock options Weighted average exercise price Aggregate intrinsic value Outstanding at beginning of period 2,614,916 $ 0.13 $ 15,624 Granted 4,081,357 1.1 Exercised (471,794 ) - Cancelled - - Outstanding at end of period 6,224,479 $ 0.78 $ 1,859 Vested and expected-to-vest at end of period 2,143,122 $ 0.13 $ 1,375 For the year ended December 31, 2016 Number of stock options Weighted average exercise price Aggregate intrinsic value Outstanding at beginning of period 1,167,693 $ 0.28 - Granted 1,447,223 (*) - Exercised - - - Cancelled - - - Outstanding at end of period 2,614,916 $ 0.13 $ 15,624 Vested and expected-to-vest at end of period 2,614,916 $ 0.13 $ 15,624 (*) Less than 1 The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the fair market value of the Common Stock and the exercise price, multiplied by the number of in-the-money stock options on those dates that would have been received by the stock option holders had all stock option holders exercised their stock options on those dates.) as of December 31, 2017 and December 31, 2016 respectively, The stock options outstanding as of December 31, 2017 and December 31, 2016, separated by exercise prices, are as follows: Exercise price Stock options outstanding as of December 31, Weighted average remaining contractual life – years as of December 31, Stock options exercisable as of December 31, $ 2017 2016 2017 2016 2017 2016 0.28 1,167,693 1,167,693 8.0 8.0 1,167,693 1,167,693 1.05 2,003,187 - 9.75 - - - 1.29 1,087,627 - 9.75 - - - 1.02 990,543 - 10 - - - (*) 975,429 1,447,223 ` 8.75 9.5 975,429 1,447,223 6,224,479 2,614,916 - - 2,143,122 2,614,916 (*) Less than 1 Compensation expense recorded by the Company in respect of its stock-based employee compensation awards in accordance with ASC 718-10 for the year ended December 31, 2017 and 2016 was $ 254 and $ 675, respectively. The fair value of the stock options is estimated at the date of grant using Black-Scholes options pricing model with the following weighted-average assumptions: Years ended December 31, 2017 2016 Expected volatility 122.5 % 77.3 % Risk-free interest 1.64 % 0.6 % Dividend yield 0 % 0 % Expected life of up to (years) 6.25 5.0 S hares Issued to Service Provider In connection with the Merger, the Company issued an aggregate of 7,802,639 restricted shares of its Common Stock to certain advisors. The fair value of the award of approximately $10,000 was estimated based on the share price of the Common Stock of $1.28 as of the date of grant. The portion of the expense in excess of the cash and other current assets acquired in the Merger, in the amount of $7,300 was included in general and administrative expenses in the Statements of Comprehensive Loss. During 2017 the Company issued an aggregate of 120,000 nonrefundable shares of Common Stock to a consultant as part of investor relations services. The Company recorded expenses of approximately $225 with respect to the issuance of these shares included in general and administrative expenses. Securities Exchange Agreement with Alpha Capital On December 16, 2016, the Company entered into a Securities Exchange Agreement with Alpha Capital, pursuant to which Alpha Capital exchanged 9,736,000 shares of common stock or rights to acquire shares of the common stock held by it, for 9,736 shares of a newly designated class of Series A Convertible Preferred Stock, par value $0.01 per share (the “Preferred Stock”). The common stock and common stock underlying the rights to acquire common stock include all of the shares of common stock issued or issuable to Alpha Capital pursuant to the Merger. The 9,735,925 shares of common stock and the rights to acquire common stock were cancelled and the Company’s issued and outstanding shares of Common Stock were reduced to 26,518,315. On May 9, 2017, the Company entered into a Securities Exchange Agreement with Alpha Capital pursuant to which the Company agreed to issue 3,254 shares of the Series A Convertible Preferred Stock, in exchange for the full satisfaction, termination and cancellation of the outstanding 6% convertible promissory note of the Company in the principal amount of approximately $2,029 issued on November 28, 2016 and held by Alpha Capital. The Series A Convertible Preferred Stock is the same series of securities as the Company’s existing Series A Convertible Preferred Stock issued in December 2016. As a result of the extinguishment of the convertible note and issuance of the preferred shares, the Company recorded a financial loss in the amount of $2,360. During the year 2017, the holder of the Series A Convertible Preferred Stock converted 8,990 shares of the Series A Convertible Preferred Stock for 8,990,000 shares of Common Stock, pursuant to the terms of conversion of the Series A Convertible Preferred Stock. Repurchase of Shares The Company intends to enter into a definitive agreement with up to three Israeli shareholders, some of whom are directors of the Company, that were former shareholders of Microbot Israel, pursuant to which the Company would repurchase, at a discount on the fair value of the share at the date of repurchase, up to $500 of Common Stock held by them, in the aggregate, if and to the extent such shareholders are unable to sell enough of their shares to cover certain of their Israeli tax liabilities resulting from the Merger. Such repurchase(s), if any, would occur only after the two-year anniversary of the Merger. The transaction is subject to negotiating final terms and entering into definitive agreements with such shareholders. The Company evaluated whether an embedded derivative that requires bifurcation exists within such shares that may be subject to repurchase. The Company concluded the fair value of such derivative instrument would be nominal and, in any case, would represent an asset to the Company as (a) the settlement requires acquiring the shares at a discount on the fair market value of the share at the time of re purchase and in no circumstances the acquisition price will be higher than approximately one dollar per share (representing 25% discount on the fair market value of the share at the merger closing date) and (b) it is assumed that the selling shareholders would use such right as last resort as such repurchase at a discount on the fair market value of such shares results in a loss to be incurred by the selling shareholders. In accordance with ASC 480-10-S99-3A (formerly EITF D-98), the Company classified the maximum amount it may be required to pay in the event the repurchase right is exercised ($500) as temporary equity.

Basic and Diluted Net Loss Per

Basic and Diluted Net Loss Per Share	12 Months Ended
	Dec. 31, 2017
Earnings Per Share [Abstract]
Basic and Diluted Net Loss Per Share	NOTE 10 - BASIC AND DILUTED NET LOSS PER SHARE The basic and diluted net loss per share and weighted average number of common shares used in the calculation of basic and diluted net loss per share are as follows (in thousands, except share and per share data): Years Ended December 31, 2017 2016 Net loss attributable to shareholders of the Company $ 7,589 $ 9,663 Net loss attributable to shareholders of preferred shares 1,582 3,954 Net loss used in the calculation of basic net loss per share $ 6,007 $ 5,709 Net loss per share $ 0.18 $ 0.40 Weighted average number of common shares 32,682,401 14,293,737 As the inclusion of common share equivalents in the calculation would be anti-dilutive for all periods presented, diluted net loss per share is the same as basic net loss per share. The weighted average number of common shares outstanding has been retroactively restated for the equivalent number of common shares received by the accounting acquirer as a result of the reverse recapitalization and reverse stock split as if these common shares had been outstanding as of the beginning of the earliest period presented.

Research and Development Expens

Research and Development Expenses, Net	12 Months Ended
	Dec. 31, 2017
Research and Development [Abstract]
Research and Development Expenses, Net	NOTE 11 - RESEARCH AND DEVELOPMENT EXPENSES, NET Years ended December 31, 2017 2016 Payroll and related expenses $ 634 $ 491 Share-based compensation 1 - Materials 266 155 Patents 66 75 Office and maintenance expenses 27 21 Rent 34 36 Professional services 174 253 Depreciation 12 7 Other 65 76 Less: Grants received from IIA (179 ) (213 ) $ 1,100 $ 901

General and Administrative Expe

General and Administrative Expenses	12 Months Ended
	Dec. 31, 2017
General and Administrative Expense [Abstract]
General and Administrative Expenses	NOTE 12 - GENERAL AND ADMINISTRATIVE EXPENSES Years ended December 31, 2017 2016 Payroll and related expenses $ 1,213 $ 45 Share-based compensation 253 676 Professional services 1,217 528 Common shares issued for services - 7,258 Travel 284 180 Marketing expenses 26 - Office and maintenance expenses 121 - Depreciation 9 - Public and Investor Relations 515 - Insurance 226 - Governmental Fees 251 Other 52 47 $ 4,167 $ 8,734

Finance Expenses, Net

Finance Expenses, Net	12 Months Ended
	Dec. 31, 2017
Other Income and Expenses [Abstract]
Finance Expenses, Net	NOTE 13 - FINANCE EXPENSES, NET Years ended December 31, 2017 2016 Bank fees and interest $ 1 $ 1 Change in fair value of derivative warrant liability (285 ) (262 ) Financing loss on debt extinguishment 2,364 - Exchange rate differences 5 (44 ) Revaluation and interest on convertible loans 237 333 $ 2,322 $ 28

Transactions and Balances with

Transactions and Balances with Interested and Related Parties	12 Months Ended
	Dec. 31, 2017
Related Party Transactions [Abstract]
Transactions and Balances With Interested and Related Parties	NOTE 14 - TRANSACTIONS AND BALANCES WITH INTERESTED AND RELATED PARTIES A. Transactions Years ended December 31, 2017 2016 Payroll and related expenses $ 851 $ - Directors fees and insurance 463 58 Subcontracted work and consulting 67 253 $ 1,381 $ 311 B. Balances As of December 31, 2017 2016 Other accounts payable $ 46 - $ 46 -

Taxes on Income

Taxes on Income	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Taxes on Income	NOTE 15 - TAXES ON INCOME The Company is subject to income taxes under the Israeli and U.S. tax laws: Corporate Tax Rates The Company is subject to Israeli corporate tax rate of 25% in the year 2016, 24% in 2017 and 23% from 2018. The Company is subject to a blended U.S. tax rate (Federal as well as state corporate tax) of 35%. On December 22, 2017, the Tax Cuts and Jobs Act (the “Tax Act”) was signed into law in the United States. The Tax Act, among other provisions, introduces changes in the U.S corporate tax rate, business related exclusions and deductions and credits, and has internationally tax consequences for companies that operate international. Most of the changes introduced in the Tax Act are effective beginning on January 1, 2018. The Tax Act introduces a reduced federal tax rate of 21% from January 1, 2018 and onward. As of December 31, 2017, the Company generated net operating losses in Israel of approximately $5,267 which may be carried forward and offset against taxable income in the future for an indefinite period. As of December 31, 2017, the Company generated net operating losses in the U.S. of approximately $2,987. Net operating losses in the United States are available through 2035. Utilization of U.S. net operating losses may be subject to substantial annual limitation due to the “change in ownership” provisions of the Internal Revenue Code of 1986 and similar state provisions. The annual limitation may result in the expiration of net operating losses before utilization. The Company is still in its development stage and has not yet generated revenues, therefore, it is more likely than not that sufficient taxable income will not be available for the tax losses to be utilized in the future. Therefore, a valuation allowance was recorded to reduce the deferred tax assets to its recoverable amounts. As of December 31, 2017 2016 Net operating loss carry-forward $ 488,603 $ 481,052 Total deferred tax assets 117,265 120,263 Valuation allowance (117,265 ) (120,263 ) Net deferred tax assets $ - $ - Reconciliation of Income Taxes: The following is a reconciliation of the taxes on income assuming that all income is taxed at the ordinary statutory corporate tax rate in Israel and the effective income tax rate: As of December 31, 2017 2016 Net loss as reported in the statements of operations $ 7,589 $ 9,663 Statutory tax rate 24 % 25 % Income Tax under statutory tax rate 1,821 2,416 Change in valuation allowance (1,821 ) (2,416 ) Actual income tax $ - $ -

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	NOTE 16 -SUBSEQUENT EVENTS CardioSert On January 4, 2018, Microbot Medical Ltd. entered into an agreement with CardioSert Ltd. to acquire certain patent-protected technology owned by CardioSert. With the closing of the acquisition expected in April 2018, CardioSert’s issued U.S. patent and three patent applications pending worldwide will be added to Microbot’s patent portfolio which will then have a patent portfolio of 25 issued/allowed patents and 15 patent applications pending worldwide. Pursuant to the Agreement, Microbot Medical Ltd made an initial payment of $50 to CardioSert and has 90-days to complete the acquisition. At the end of the 90-day period, at Microbot’s sole option, CardioSert shall assign and transfer the Technology to Microbot Medical Ltd and Microbot Medical Ltd shall pay to CardioSert additional amounts and options as determined in the agreements. The Agreement may be terminated by Microbot at any time during the 90-day pre-closing period, and otherwise for convenience upon 90-days’ notice. The Agreement may be terminated by CardioSert in case the first commercial sale does not occur by the third anniversary of the date of signing of the Agreement except in the event that Microbot has invested more than $2,000 in certain development stages, or the first commercial sale does not occur within 50 months. In each of the above termination events, or in case of breach by Microbot, CardioSert shall have the right to buy back the Technology from Microbot for $1.00, upon 60 days prior written notice, but only 1 year after such termination. Additionally, the Agreement may be terminated by either party upon breach of the other (subject to cure). CardioSert agreed to assist Microbot in the development of the Technology for a minimum of one year, for a monthly consultation fee of NIS40,000 covering up to 60 consulting hours per month. Share Capital Developments In 2018, through March 30, 2018, the Company issued an aggregate of 1,500,000 shares of its Common Stock upon the conversion of an aggregate of 1,500 shares of its Series A Convertible Preferred Stock.

Summary of Significant Accoun24

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Basis of Presentation	A. Basis of Presentation The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”).
Financial Statement in U.S. Dollars	B. Financial Statement in U.S. Dollars The functional currency of the Company is the U.S. dollar (“dollar”) since the dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future. Transactions and balances denominated in dollars are presented at their original amounts. Transactions and balances denominated in foreign currencies have been re-measured to dollars in accordance with the provisions of ASC 830-10, “Foreign Currency Translation”. All transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the statement of operations as financial income or expenses, as appropriate.
Cash and Cash Equivalents	C. Cash and Cash Equivalents Cash and cash equivalents consist of cash and demand deposits in banks, and other short-term liquid investments (primarily interest-bearing time deposits) with original maturities of less than three months.
Fair Value of Financial Instruments	D. Fair Value of Financial Instruments The carrying values of cash and cash equivalents, other receivable and other accounts payable and accrued liabilities approximate their fair value due to the short-term maturity of these instruments. The Company measures the fair value of certain of its financial instruments (such as the derivative warrant liabilities) on a recurring basis. The method of determining the fair value of derivative warrant liabilities is discussed in Note 7. A fair value hierarchy is used to rank the quality and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value will be classified and disclosed in one of the following three categories: ● Level 1 ● Level 2 ● Level 3
Fixed Assets	E. Fixed Assets Fixed assets are presented at costs less accumulated depreciation. Depreciation is calculated based on the straight-line method over the estimated useful lives of the assets, as the following annual rates: % Research equipment and software 25-33 Furniture and office equipment 7
Liabilities Due to Termination of Employment Agreements	F. Liabilities Due to Termination of Employment Agreements Under Israeli employment laws, employees of Microbot Israel are included under Article 14 of the Severance Compensation Act, 1963 (“Article 14”). According to Article 14, these employees are entitled to monthly deposits made by Microbot Israel on their behalf with insurance companies. Payments in accordance with Article 14 release Microbot Israel from any future severance payments (under the Israeli Severance Compensation Act, 1963) with respect of those employees. The aforementioned deposits are not recorded as an asset in the Company’s balance sheet.
Basic and Diluted Net Loss Per Share	G. Basic and Diluted Net Loss Per Share Basic net loss per share is computed by dividing net loss, as adjusted to include the weighted average number of common shares outstanding during the year. Common shares and preferred shares contingently issuable for little or no cash are included in basic net loss per share on an as issued basis. Diluted net loss per share is computed by dividing net loss, as adjusted to include preferred shares dividend participation rights of preferred shares outstanding during the year as well as of preferred shares that would have been outstanding if all potentially dilutive preferred shares had been issued, by the weighted average number of common shares outstanding during the year, plus the number of common shares that would have been outstanding if all potentially dilutive common shares had been issued, using the treasury stock method, in accordance with ASC 260-10 “Earnings per Share”. All outstanding stock options and warrants have been excluded from the calculation of the diluted loss per share for the years ended December 31, 2017 and December 31, 2016, since all such securities have an anti-dilutive effect. The weighted average number of shares outstanding has been retroactively restated for the equivalent number of shares received by the accounting acquirer as a result of the reverse recapitalization as if these shares had been outstanding as of the beginning of the earliest period presented.
Research and Development Expenses, Net	H. Research and Development Expenses, Net Research and development expenses are charged to the statement of operations as incurred. Grants for funding of approved research and development projects are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred and applied as a deduction from the research and development expenses.
Convertible Notes	I. Convertible Notes Proceeds from the sale of debt securities with a conversion feature are allocated to equity based on the intrinsic value of such conversion feature in accordance with ASC 470-20 “Debt with Conversion and Other Options”, with a corresponding discount on the debt instrument recorded in liabilities which is amortized in finance expense over the term of the notes. Convertible notes with characteristics of both liabilities and equity are classified as either debt or equity based on the characteristics of its monetary value, with convertible notes classified as debt being measured at fair value, in accordance with ASC 480-10, “Accounting for Certain Financial instruments with Characteristics of both Liabilities and Equity”.
Share-Based Compensation	J. Share-Based Compensation The Company applies ASC 718-10, “Share-Based Payment,” which requires the measurement and recognition of compensation expenses for all share-based payment awards made to employees and directors including stock options under the Company’s stock plans based on estimated fair values. ASC 718-10 requires companies to estimate the fair value of stock options using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company’s statement of operations. The Company accounts for stock-based compensation awards to non-employees in accordance with FASB ASC 505-50, “Equity-Based Payments to Non-Employees” (“FASB ASC 505-50”). Under FASB ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The Company estimates the fair value of stock options granted as share-based payment awards using a Black-Scholes options pricing model. The option-pricing model requires a number of assumptions, of which the most significant are expected volatility and the expected option term (the time from the grant date until the options are exercised or expire). Expected volatility is estimated based on volatility of similar companies in the technology sector for equity awards granted prior to the Merger and on the Company’s trading share price for equity awards granted subsequent to the Merger. The Company has historically not paid dividends and has no foreseeable plans to issue dividends. The risk-free interest rate is based on the yield from governmental zero-coupon bonds with an equivalent term. The expected stock option term is calculated for stock options granted to employees and directors using the “simplified” method. Grants to non-employees are based on the contractual term. Changes in the determination of each of the inputs can affect the fair value of the stock options granted and the results of operations of the Company.
Reclassification	K. Reclassification Certain prior year amounts have been reclassified to conform to the current year presentation.
Transaction Costs	L. Transaction Costs Transaction costs incurred in the Merger were charged directly to equity to the extent of cash and net other current assets acquired. Transaction costs in excess of cash acquired were charged to general and administrative expenses.
Income Taxes	M. Income Taxes The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of December 31, 2017 and 2016, the Company had a full valuation allowance against deferred tax assets.
Recent Accounting Standards	N. Recent Accounting Standards In May 2014, the FASB issued ASU 2014-09 “Revenue from Contracts with Customers” to provide a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. The ASU supersedes most current revenue recognition guidance, including industry-specific guidance. The FASB subsequently issued ASU 2015-14, ASU 2016-08 and ASU 2016-12, which clarified the guidance, provided scope improvements and amended the effective date of ASU 2014-09. As a result, ASU 2014-09 becomes effective for the Company in the first quarter of 2018, with early adoption permitted. The Company has not yet generated revenues to date, and does not yet know the impact the standard may have on its consolidated financial statements. In February 2016, the FASB issued ASU 2016-02 “Leases” to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. For operating leases, the ASU requires a lessee to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments, on its balance sheet. The ASU retains the current accounting for lessors and does not make significant changes to the recognition, measurement, and presentation of expenses and cash flows by a lessee. This ASU is effective for the Company in the first quarter of 2019, with early adoption permitted. The Company continues to evaluate the effect of the adoption of this ASU and expects the adoption will result in an increase in the assets and liabilities on the consolidated balance sheets for operating leases (refer to Note 8) and will likely have an insignificant impact on the consolidated statements of comprehensive loss. In June 2016, the FASB issued ASU 2016-13 “Financial Instruments – Credit Losses” to improve information on credit losses for financial assets and net investment in leases that are not accounted for at fair value through net income. The ASU replaces the current incurred loss impairment methodology with a methodology that reflects expected credit losses. This ASU is effective for the Company in the first quarter of 2020, with early adoption permitted. The Company is currently evaluating the effect the adoption of this ASU will have on its consolidated financial statements. In November 2016, the FASB issued ASU 2016-18 “Restricted Cash” to provide guidance on the presentation of restricted cash in the statement of cash flows. Currently, the statement of cash flows explained the change in cash and cash equivalents for the period. The ASU requires that the statement of cash flows explain the change in cash, cash equivalents and restricted cash for the period. The ASU is effective for the Company in the first quarter of 2018, with early adoption permitted. The Company does not expect the adoption to have a material effect on the statements of cash flows as the Company’s restricted cash is not expected to be material. In May 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-09, “Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting,” which clarifies when a change to terms or conditions of a share-based payment award must be accounted for as a modification. The new guidance requires modification accounting if the vesting condition, fair value or the award classification is not the same both before and after a change to the terms and conditions of the award. The new guidance is effective for the Company on a prospective basis beginning on January 1, 2018 and early adoption is permitted. The Company does not expect to change terms or conditions of share-based payment awards, and therefore, does not expect the adoption of this standard to have a material impact on its consolidated financial statements. In July 2017, the FASB issued ASU 2017-11, which includes Part I “Accounting for Certain Financial Instruments with Down Round Features” and Part II “Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-Controlling Interests with a Scope Exception”. The ASU makes limited changes to the Board’s guidance on classifying certain financial instruments as either liabilities or equity. The ASU’s objective is to improve (1) the accounting for instruments with “down-round” provisions and (2) the readability of the guidance in ASC 480 on distinguishing liabilities from equity by replacing the indefinite deferral of certain pending content with scope exceptions. The ASU is effective for the Company in the first quarter of 2019, with early adoption permitted. The Company has derivative warranty liabilities as discussed in Note 7 which upon adoption of the new standard are expected to be classified as equity.

Summary of Significant Accoun25

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Estimated Useful Lives of Property and Equipment	Fixed assets are presented at costs less accumulated depreciation. Depreciation is calculated based on the straight-line method over the estimated useful lives of the assets, as the following annual rates: % Research equipment and software 25-33 Furniture and office equipment 7

Other Current Assets (Tables)

Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2017
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Other Current Assets	As of December 31, 2017 2016 Deposit in escrow account (*) $ - $ 400 Government institutions 35 15 Prepaid expenses and others 81 191 $ 116 $ 606 (*) Purchase Agreement with BOCO

Fixed Assets, Net (Tables)

Fixed Assets, Net (Tables)	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Summary of Fixed Assets, Net	As of December 31, 2017 2016 Cost: Research equipment and software $ 76 $ 54 Furniture and office equipment 92 56 168 110 Accumulated Depreciation: Research equipment and software 42 29 Furniture and office equipment 36 28 78 57 $ 90 $ 53

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2017
Payables and Accruals [Abstract]
Summary of Accrued Liabilities	As of December 31, 2017 2016 Employees $ 64 $ 102 Government institution 56 24 Other current liabilities 330 145 $ 450 $ 271

Convertible Loan from Shareho29

Convertible Loan from Shareholders (Tables)	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Schedule of Carrying Value of Convertible Note	The carrying value of the Convertible Note as of the periods below was calculated as follow: As of December 31, 2017 2016 Convertible note $ - $ 2,029 Unamortized discount - (1,963 ) Accrued interest - 10 $ - $ 76

Derivative Warrant Liabilities

Derivative Warrant Liabilities (Tables)	12 Months Ended
	Dec. 31, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Outstanding Warrants Liabilities	The remaining outstanding warrants and terms as of December 31, 2017 and 2016 is as follows: Issuance Date Outstanding as of December 31, 2016 Outstanding as of December 31, 2017 Exercise Price Exercisable as of December 31, 2017 Exercisable Through Series A (2011) 64,230 - $ 151.20 - December 2016 Series A (2013) 57,814 57,814 $ 194.40 57,814 October 2018 Series A (2013) 2,718 2,718 $ 183.60 2,718 April 2023 Series A (2015) 10,139 10,139 $ 91.80 10,139 April 2020 Series A (2016)(a) 10,047 9,279 $ 2.70 9,279 March 2018 Series B (2016)(a) 41,116 41,116 $ 2.70 41,116 March 2022 (a) These warrants contain a full ratchet anti-dilution price protection so that, in most situations upon the issuance of any common stock or securities convertible into common stock at a price below the then-existing exercise price of the outstanding warrants, the warrant exercise price will be reset to the lower common stock sales price. As such anti-dilution price protection does not meet the specific conditions for equity classification, the Company is required to classify the fair value of these warrants as a liability, with changes in fair value to be recorded as income (loss) due to change in fair value of warrant liability. The estimated fair value of our warrant liability at December 31, 2017 and December 31, 2016, was approximately $28 and $313, respectively.
Schedule of Valuation of Derivative Warrant Liabilities	The following table summarizes the observable inputs used in the valuation of the derivative warrant liabilities as of December 31, 2017 and December 31, 2016 : Series A (2011) Series A (2013) Series A (2013) Series A (2015) Series A (2016) Series B (2016) Total Balances at December 31, 2016 $ - $ 12 $ 9 $ 22 $ 43 $ 227 $ 313 Exercised - - - - - - - Cancelled - - - - - - - Changes in fair value - (12 ) (9 ) (22 ) (43 ) (199 ) (285 ) Balances at December 31, 2017 $ - $ - $ - $ - $ (* ) $ 28 $ 28 (*) Less than 1
Schedule of Fair Value Assumption	The following table summarizes the observable inputs used in the valuation of the derivative warrant liabilities as of December 31, 2017 and December 31, 2016: As of December 31, 2017 As of December 31, 2016 Series A (2016) Series B (2016) Series A (2016) Series B (2016) Share price $ 1.02 $ 1.02 $ 6.10 $ 6.10 Exercise price $ 2.70 $ 2.70 $ 2.70 $ 2.70 Expected volatility 60 % 119 % 380 % 380 % Risk-free interest 1.24 % 1.89 % 0.85 % 1.93 % Dividend yield — — — — Expected life of up to (years) 0.25 4.25 1.2 5.2
Schedule of Liabilities Measured on a Recurring Basis	Activity in such liabilities measured on a recurring basis is as follows: Derivative warrant liabilities As of December 31, 2016 $ 313 Revaluation of warrants (285 ) Exercise warrants (* ) As of December 31, 2017 $ 28 (*) Less than 1 Derivative warrant liabilities As of November 30, 2016 $ 575 Revaluation of warrants (262 ) Exercise warrants (* ) As of December 31, 2016 $ 313 (*) Less than 1

Share Capital (Tables)

Share Capital (Tables)	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Summary of Stock Option Activity	A summary of the Company’s option activity related to options to employees and directors, and related information is as follows: For the year ended December 31, 2017 Number of stock options Weighted average exercise price Aggregate intrinsic value Outstanding at beginning of period 2,614,916 $ 0.13 $ 15,624 Granted 4,081,357 1.1 Exercised (471,794 ) - Cancelled - - Outstanding at end of period 6,224,479 $ 0.78 $ 1,859 Vested and expected-to-vest at end of period 2,143,122 $ 0.13 $ 1,375 For the year ended December 31, 2016 Number of stock options Weighted average exercise price Aggregate intrinsic value Outstanding at beginning of period 1,167,693 $ 0.28 - Granted 1,447,223 (*) - Exercised - - - Cancelled - - - Outstanding at end of period 2,614,916 $ 0.13 $ 15,624 Vested and expected-to-vest at end of period 2,614,916 $ 0.13 $ 15,624 (*) Less than 1
Schedule of Stock Options Outstanding	The stock options outstanding as of December 31, 2017 and December 31, 2016, separated by exercise prices, are as follows: Exercise price Stock options outstanding as of December 31, Weighted average remaining contractual life – years as of December 31, Stock options exercisable as of December 31, $ 2017 2016 2017 2016 2017 2016 0.28 1,167,693 1,167,693 8.0 8.0 1,167,693 1,167,693 1.05 2,003,187 - 9.75 - - - 1.29 1,087,627 - 9.75 - - - 1.02 990,543 - 10 - - - (*) 975,429 1,447,223 ` 8.75 9.5 975,429 1,447,223 6,224,479 2,614,916 - - 2,143,122 2,614,916 (*) Less than 1
Schedule of Stock Options Valuation Assumptions	The fair value of the stock options is estimated at the date of grant using Black-Scholes options pricing model with the following weighted-average assumptions: Years ended December 31, 2017 2016 Expected volatility 122.5 % 77.3 % Risk-free interest 1.64 % 0.6 % Dividend yield 0 % 0 % Expected life of up to (years) 6.25 5.0

Basic and Diluted Net Loss Pe32

Basic and Diluted Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2017
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Net Loss Per Share	The basic and diluted net loss per share and weighted average number of common shares used in the calculation of basic and diluted net loss per share are as follows (in thousands, except share and per share data): Years Ended December 31, 2017 2016 Net loss attributable to shareholders of the Company $ 7,589 $ 9,663 Net loss attributable to shareholders of preferred shares 1,582 3,954 Net loss used in the calculation of basic net loss per share $ 6,007 $ 5,709 Net loss per share $ 0.18 $ 0.40 Weighted average number of common shares 32,682,401 14,293,737

Research and Development Expe33

Research and Development Expenses, Net (Tables)	12 Months Ended
	Dec. 31, 2017
Research and Development [Abstract]
Schedule of Research and Development Expenses	Years ended December 31, 2017 2016 Payroll and related expenses $ 634 $ 491 Share-based compensation 1 - Materials 266 155 Patents 66 75 Office and maintenance expenses 27 21 Rent 34 36 Professional services 174 253 Depreciation 12 7 Other 65 76 Less: Grants received from IIA (179 ) (213 ) $ 1,100 $ 901

General and Administrative Ex34

General and Administrative Expenses (Tables)	12 Months Ended
	Dec. 31, 2017
General and Administrative Expense [Abstract]
Schedule of General and Administrative Expenses	Years ended December 31, 2017 2016 Payroll and related expenses $ 1,213 $ 45 Share-based compensation 253 676 Professional services 1,217 528 Common shares issued for services - 7,258 Travel 284 180 Marketing expenses 26 - Office and maintenance expenses 121 - Depreciation 9 - Public and Investor Relations 515 - Insurance 226 - Governmental Fees 251 Other 52 47 $ 4,167 $ 8,734

Finance Expenses, Net (Tables)

Finance Expenses, Net (Tables)	12 Months Ended
	Dec. 31, 2017
Other Income and Expenses [Abstract]
Summary of Finance Expenses, Net	Years ended December 31, 2017 2016 Bank fees and interest $ 1 $ 1 Change in fair value of derivative warrant liability (285 ) (262 ) Financing loss on debt extinguishment 2,364 - Exchange rate differences 5 (44 ) Revaluation and interest on convertible loans 237 333 $ 2,322 $ 28

Transactions and Balances wit36

Transactions and Balances with Interested and Related Parties (Tables)	12 Months Ended
	Dec. 31, 2017
Related Party Transactions [Abstract]
Schedule of Related Party Transaction and Balances	A. Transactions Years ended December 31, 2017 2016 Payroll and related expenses $ 851 $ - Directors fees and insurance 463 58 Subcontracted work and consulting 67 253 $ 1,381 $ 311 B. Balances As of December 31, 2017 2016 Other accounts payable $ 46 - $ 46 -

Taxes on Income (Tables)

Taxes on Income (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets	As of December 31, 2017 2016 Net operating loss carry-forward $ 488,603 $ 481,052 Total deferred tax assets 117,265 120,263 Valuation allowance (117,265 ) (120,263 ) Net deferred tax assets $ - $ -
Schedule of Statutory Corporate Tax Rate and Effective Income Tax Rate	The following is a reconciliation of the taxes on income assuming that all income is taxed at the ordinary statutory corporate tax rate in Israel and the effective income tax rate: As of December 31, 2017 2016 Net loss as reported in the statements of operations $ 7,589 $ 9,663 Statutory tax rate 24 % 25 % Income Tax under statutory tax rate 1,821 2,416 Change in valuation allowance (1,821 ) (2,416 ) Actual income tax $ - $ -

General (Details Narrative)

General (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Nov. 28, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Common stock, par value		$ 0.01	$ 0.01
Reverse stock split	one-to-nine Reverse Stock Split
Cash and cash equivalent		$ 10,787	$ 2,709	$ 437
Microbot Israel [Member]
Conversion value of shares	2.9 shares
Common stock, par value	$ 0.01
Reverse stock split	one for nine reverse stock split
Conversion option to purchase common stock	2,614,916
Restricted shares issued	7,802,639
Microbot Israel [Member] | Former Microbot Israel Shareholders [Member]
Conversion of stock number of common stock issued	26,550,974

Summary of Significant Accoun39

Summary of Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Details)	12 Months Ended
	Dec. 31, 2017
Research Equipment and Software [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	25 years
Research Equipment and Software [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	33 years
Furniture and Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	7 years

Other Current Assets (Details N

Other Current Assets (Details Narrative) $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)
Asset consideration	$ 4,000
Proceeds from other receivables	320
Payment of related party	80
Sale of assets	3,500
June 2016 Agreements [Member]
Asset consideration	$ 495
Percentage of severance award	50.00%
Escrow Account [Member]
Asset consideration	$ 400
Prior to November 11, 2016 [Member]
Asset consideration	$ 300

Other Current Assets - Schedule

Other Current Assets - Schedule of Other Current Assets - (Details) - USD ($) $ in Thousands		Dec. 31, 2017	Dec. 31, 2016
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Deposit in escrow account	[1]		$ 400
Government institutions		35	15
Prepaid expenses and others		81	191
Total Other current assets		$ 116	$ 606
[1]	Purchase Agreement with BOCO. On November 11, 2016, the Company together with two of its wholly-owned subsidiaries, Stem Cell Sciences Holdings Limited and StemCells California, Inc. (collectively, with the Company, the “Sellers”), entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with BOCO Silicon Valley, Inc., a California corporation and wholly-owned subsidiary of Bright Oceans Corporation (“BOCO US”).

Fixed Assets, Net - Summary of

Fixed Assets, Net - Summary of Fixed Assets, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Cost	$ 168	$ 110
Accumulated Depreciation	78	57
Fixed Assets, net	90	53
Research Equipment and Software [Member]
Cost	76	54
Accumulated Depreciation	42	29
Furniture and Office Equipment [Member]
Cost	92	56
Accumulated Depreciation	$ 36	$ 28

Accrued Liabilities - Summary o

Accrued Liabilities - Summary of Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Payables and Accruals [Abstract]
Employees	$ 64	$ 102
Government institution	56	24
Other current liabilities	330	145
Total Accrued Liabilities	$ 450	$ 271

Convertible Loan from Shareho44

Convertible Loan from Shareholders (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Nov. 28, 2016	Nov. 28, 2016	Aug. 31, 2016	Jul. 07, 2016	Oct. 08, 2015	Sep. 30, 2016	Dec. 31, 2017	Dec. 31, 2016	Aug. 15, 2016	May 11, 2016
Loans receivable								$ 750
Loan [Member]
Common stock issued in connection with conversion of loan at the merger	2,242,939
Microbot Israel [Member]
Loans receivable					$ 419
Loan bears interest rate					10.00%
Proceeds from exercise of warrant						$ 410
The loan bears interest rate										10.00%
Debt, discount rate		20.00%					20.00%
Microbot Israel [Member] | Series A Preferred Shares [Member]
Debt conversion, preferred shares issued				1,315,023
Debt conversion, warrant issued				1,188,275
Exercise price of warrants				$ 1
Alpha Capital [Member] | Merger Agreement [Member]
Secured note principal amount			$ 2,000
Principal and accrued interest of note			$ 2,029
Alpha Capital [Member] | Secured Note [Member]
Loan bears interest rate									6.00%
Secured note principal amount									$ 2,000
Alpha Capital [Member] | Convertible Note [Member]
Loan bears interest rate							6.00%
Principal and accrued interest of note							$ 2,029
Debt maturity date							Nov. 28, 2019
Convertible note, conversion price							$ 0.64

Convertible Loan from Shareho45

Convertible Loan from Shareholders - Schedule of Carrying Value of Convertible Note (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Debt Disclosure [Abstract]
Convertible note		$ 2,029
Unamortized discount		(1,963)
Accrued interest		10
Convertible notes		$ 76

Derivative Warrant Liabilitie46

Derivative Warrant Liabilities (Details Narrative) - $ / shares	1 Months Ended	12 Months Ended
	Aug. 31, 2016	Dec. 31, 2017	Mar. 31, 2017
Common shares issued upon exercise of warrants		531,814
Warrant outstanding		578,081
Number of common stock issued in prior to the merger		531,814
Warrant calculation description		The Company recalculated the value of warrants by applying a +/- 5% changes to the input variables in the Black-Scholes model that vary overtime, namely, the volatility and the risk-free rate. A 5.0% decrease in volatility would decrease the value of the warrants to $27; a 5.0% increase in volatility would increase the value of the warrants to $29. A 5.0% decrease or increase in the risk-free rate would not have materially changed the value of the warrants; the value of the warrants is not strongly correlated with small changes in interest rates.
Volatility rate		5.00%
Risk free rate		5.00%
Warrant [Member]
Cashless exercise warrants			768
Common Stock [Member]
Cashless exercise warrants			359
2016 Series A and B Warrants [Member]
Warrants exercise price	$ 0.30
2011 Series A Warrants [Member]
Warrants exercise price	$ 0.30

Derivative Warrant Liabilitie47

Derivative Warrant Liabilities - Schedule of Outstanding Warrants Liabilities (Details) - $ / shares		12 Months Ended
		Dec. 31, 2017	Dec. 31, 2016
Series A (2011) [Member]
Number of Warrant Outstanding, shares			64,230
Warrant Exercise Price, Per Share		$ 151.20
Warrant Exercisable
Number of Warrant Exercisable, Period		December 2,016
Series A (2013) [Member]
Number of Warrant Outstanding, shares		57,814	57,814
Warrant Exercise Price, Per Share		$ 194.40
Warrant Exercisable		57,814
Number of Warrant Exercisable, Period		October 2,018
Series A (2013) [Member]
Number of Warrant Outstanding, shares		2,718	2,718
Warrant Exercise Price, Per Share		$ 183.60
Warrant Exercisable		2,718
Number of Warrant Exercisable, Period		April 2,023
Series A (2015) [Member]
Number of Warrant Outstanding, shares		10,139	10,139
Warrant Exercise Price, Per Share		$ 91.80
Warrant Exercisable		10,139
Number of Warrant Exercisable, Period		April 2,020
Series A (2016) [Member]
Number of Warrant Outstanding, shares	[1]	9,279	10,047
Warrant Exercise Price, Per Share	[1]	$ 2.70
Warrant Exercisable	[1]	9,279
Number of Warrant Exercisable, Period	[1]	March 2,018
Series B (2016) [Member]
Number of Warrant Outstanding, shares	[1]	41,116	41,116
Warrant Exercise Price, Per Share	[1]	$ 2.70
Warrant Exercisable	[1]	41,116
Number of Warrant Exercisable, Period	[1]	March 2,022
[1]	These warrants contain a full ratchet anti-dilution price protection so that, in most situations upon the issuance of any common stock or securities convertible into common stock at a price below the then-existing exercise price of the outstanding warrants, the warrant exercise price will be reset to the lower common stock sales price. As such anti-dilution price protection does not meet the specific conditions for equity classification, the Company is required to classify the fair value of these warrants as a liability, with changes in fair value to be recorded as income (loss) due to change in fair value of warrant liability. The estimated fair value of our warrant liability at December 31, 2017 and December 31, 2016, was approximately $28 and $313, respectively.

Derivative Warrant Liabilitie48

Derivative Warrant Liabilities - Schedule of Outstanding Warrants Liabilities (Details) (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Estimated fair value of warrant liability	$ 28	$ 313

Derivative Warrant Liabilitie49

Derivative Warrant Liabilities - Schedule of Valuation of Derivative Warrant Liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017		Dec. 31, 2016
Balances at December 31, 2016	$ 313
Exercised
Cancelled
Changes in fair value	(285)		$ (262)
Balances at December 31, 2017	28		313
Series A (2011) [Member]
Balances at December 31, 2016
Exercised
Cancelled
Changes in fair value
Balances at December 31, 2017
Series A (2013) [Member]
Balances at December 31, 2016	12
Exercised
Cancelled
Changes in fair value	(12)
Balances at December 31, 2017			12
Series A (2013) [Member]
Balances at December 31, 2016	9
Exercised
Cancelled
Changes in fair value	(9)
Balances at December 31, 2017			9
Series A (2015) [Member]
Balances at December 31, 2016	22
Exercised
Cancelled
Changes in fair value	(22)
Balances at December 31, 2017			22
Series A (2016) [Member]
Balances at December 31, 2016	43
Exercised
Cancelled
Changes in fair value	(43)
Balances at December 31, 2017		[1]	43
Series B (2016) [Member]
Balances at December 31, 2016	227
Exercised
Cancelled
Changes in fair value	(199)
Balances at December 31, 2017	$ 28		$ 227
[1]	Less than 1

Derivative Warrant Liabilitie50

Derivative Warrant Liabilities - Schedule of Fair Value Assumption (Details) - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Expected volatility	5.00%
Risk-free interest	5.00%
Series A (2016) [Member]
Share price	$ 1.02	$ 6.10
Exercise price	$ 2.70	$ 2.70
Expected volatility	60.00%	380.00%
Risk-free interest	1.24%	0.85%
Dividend yield	0.00%	0.00%
Expected life of up to (years)	2 months 30 days	1 year 2 months 12 days
Series B (2016) [Member]
Share price	$ 1.02	$ 6.10
Exercise price	$ 2.70	$ 2.70
Expected volatility	119.00%	380.00%
Risk-free interest	1.89%	1.93%
Dividend yield	0.00%	0.00%
Expected life of up to (years)	4 years 2 months 30 days	5 years 2 months 12 days

Derivative Warrant Liabilitie51

Derivative Warrant Liabilities - Schedule of Liabilities Measured on a Recurring Basis (Details) - USD ($) $ in Thousands		1 Months Ended	12 Months Ended
		Dec. 31, 2016	Dec. 31, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Beginning balance		$ 575	$ 313
Revaluation of warrants		(262)	(285)
Exercise warrants	[1]
Ending balance		$ 313	$ 28
[1]	Less than 1

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	Jun. 08, 2017	May 31, 2017	Dec. 31, 2016	Jun. 30, 2016	Dec. 31, 2012	Dec. 31, 2017
Compensation commitments						$ 400,000
Office Lease Agreement [Member]
Lease term				Feb. 28, 2018
Monthly lease payment				$ 3,000
Cars Lease Agreement [Member]
Lease term			Dec. 31, 2019
Monthly lease payment			$ 2,500
Officer Lease Agreement [Member]
Lease term		Dec. 31, 2020
Monthly lease payment		$ 14,000
Guarantees amount		$ 55,000
Securities Exchange Agreement [Member]
Purchase price of Plaintiffs	$ 3,375,000
Loss contingency, damages sought	$ 1,000,000
Technician Research And Development Foundation Limited [Member] | Minimum [Member]
Royalties payable as percentage of future sales					1.50%
Technician Research And Development Foundation Limited [Member] | Maximum [Member]
Royalties payable as percentage of future sales					3.00%
Israeli Innovation Authority [Member] | 2013 Through 2017 [Member]
Total grants obtained						$ 1,183,000
Royalties payable as percentage of future sales						3.00%

Share Capital (Details Narrativ

Share Capital (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Dec. 28, 2017	Dec. 06, 2017	Sep. 14, 2017	Jun. 05, 2017	May 09, 2017	Jan. 05, 2017	Dec. 27, 2016	Dec. 16, 2016	Nov. 28, 2016	May 02, 2016	Nov. 30, 2017	May 31, 2017	Sep. 30, 2014	Dec. 31, 2017	Dec. 31, 2016		Mar. 31, 2017	Oct. 08, 2015
Preferred stock, par value														$ 0.01	$ 0.01
Authorized capital stock														221,000,000
Common stock, shares authorized														220,000,000	220,000,000
Common stock, par value														$ 0.01	$ 0.01
Preferred stock, shares authorized														1,000,000	1,000,000
Common stock, shares issued														29,880,289	15,848,136
Common stock, shares outstanding														29,880,289	15,848,136
Preferred stock, shares issued														4,001	9,736
Preferred stock, shares outstanding														4,001	9,736
Reverse stock splits									36,254,240
Proceeds from issuance of shares														$ 12,702
Number of stock options granted														4,081,357	1,447,223
Weighted-average exercise price per share, granted														$ 1.1		[1]
Stock-based employee compensation														$ 254	$ 675
Number of option exercised														(471,794)
Loss on extinguishment of convertible note														$ 2,364
Repurchase of common stock														$ 500
Fair market value percentage														25.00%
Temporary equity value														$ 500
General and Administrative Expense [Member]
Stock-based employee compensation														253	676
Number of shares issued for services, value															$ (7,258)
Microbot Israel [Member]
Common stock, par value									$ 0.01
Loan bears interest rate																		10.00%
Microbot Israel [Member] | General and Administrative Expense [Member]
Stock-based employee compensation														675
Alpha Capital [Member]
Preferred stock, par value								$ 0.01
Rights to acquire shares of common stock								9,736,000
Designated preferred stock								9,736
Number of shares issued during period								9,735,925
Common stock shares issued and outstanding reduced during the period								26,518,315
Board of Directors [Member]
Number of stock options granted	990,543	190,475
Weighted-average exercise price per share, granted	$ 1.02	$ 1.05
Stock option vested term	3 years	3 years
Board of Directors [Member] | General and Administrative Expense [Member]
Stock-based employee compensation														5
Board of Directors [Member] | Microbot Israel [Member]
Common stock, par value										$ 0.001
Number of stock options granted										500,000			403,592
Number of stock option granted as adjustment of reflect merger										1,447,223			1,167,693
Weighted-average exercise price per share, granted										$ 1.35			$ 0.80
Stock option merger retroactively adjusted exercise price per share										$ 0.47			$ 0.28
Hazel Gadot [Member]
Number of stock options granted			1,812,721
Weighted-average exercise price per share, granted			$ 1.05
Hazel Gadot [Member] | General and Administrative Expense [Member]
Stock-based employee compensation														156
Hezi Himelfarb [Member]
Number of stock options granted			1,087,627
Weighted-average exercise price per share, granted			$ 1.29
Stock option vested term			3 years
Hezi Himelfarb [Member] | General and Administrative Expense [Member]
Stock-based employee compensation														92
Employees [Member]
Number of stock options granted	990,543
Employees and Directors [Member] | General and Administrative Expense [Member]
Stock-based employee compensation														$ 1
Employees and Consultant [Member]
Common stock, par value											$ 0.001
Number of option exercised											471,794
Advisors [Member] | Restricted Stock [Member]
Common stock price per share														$ 1.28
Number of shares issued for services														7,802,639
Number of shares issued for services, value														$ 10,000
Advisors [Member] | General and Administrative Expense [Member] | Restricted Stock [Member]
Stock-based employee compensation														7,300
Consultant [Member]
Stock-based employee compensation														$ 225
Number of shares issued for services														120,000
Purchaser [Member]
Number of common stock shares sold during the period						700,000
Common stock price per share						$ 5
Proceeds from issuance of shares						$ 3,500
Placement agent fee						$ 210
Investor [Member]
Number of common stock shares sold during the period				3,750,000
Common stock price per share				$ 2.70
Proceeds from issuance of shares				$ 10,125
Placement agent fee				$ 922
Minimum [Member]
Common stock, shares authorized									200,000,000
Minimum [Member] | Hazel Gadot [Member]
Stock option vested term			3 years
Maximum [Member]
Common stock, shares authorized									220,000,000
Maximum [Member] | Hazel Gadot [Member]
Stock option vested term			5 years
Warrant [Member]
Cashless exercise warrants																	768
Common Stock [Member]
Conversion of stock into shares														8,990,000
Cashless exercise warrants																	359
Common stock, shares issued														40,583,127
Common stock, shares outstanding														40,583,127
Rights to acquire shares of common stock							9,735,925
Number of option exercised														471,794
Number of shares issued during period														4,450,000
Series A Convertible Preferred Stock [Member]
Conversion of stock into shares														8,990
Preferred stock, shares issued														4,001
Preferred stock, shares outstanding														4,001
Series A Convertible Preferred Stock [Member]
Preferred stock, par value												$ 0.01			$ 0.01
Conversion of stock into shares												1,000			1,000
Series A Convertible Preferred Stock [Member] | Securities Purchase Agreement [Member]
Loan bears interest rate					6.00%
Debt maturity date					Nov. 28, 2016
Debt instrument face amount					$ 2,029
Series A Convertible Preferred Stock [Member] | Alpha Capital [Member] | Securities Purchase Agreement [Member]
Number of shares issued during period					3,254
Loss on extinguishment of convertible note					$ 2,360
Common Stock [Member]
Cashless exercise warrants																	359
Series A Preferred Shares [Member]
Designated preferred stock							9,736
[1]	Less than 1

Share Capital - Summary of Stoc

Share Capital - Summary of Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Equity [Abstract]
Number of Stock Options Outstanding, Outstanding at Beginning Balance	2,614,916	1,167,693
Number of Stock Options Outstanding, Granted	4,081,357	1,447,223
Number of Stock Options Outstanding, Exercised	(471,794)
Number of Stock Options Outstanding, Cancelled
Number of Stock Options Outstanding, Outstanding at Ending Balance	6,224,479	2,614,916
Number of Stock Options Outstanding, Vested and expected-to-vest at end of period	2,143,122	2,614,916
Weighted Average Exercise Price, Outstanding at Beginning Balance	$ 0.13	$ 0.28
Weighted Average Exercise Price, Granted	1.1		[1]
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Cancelled
Weighted Average Exercise Price, Outstanding at Ending Balance	0.78	0.13
Weighted Average Exercise Price, Vested and expected-to-vest at end of period	$ 0.13	$ 0.13
Aggregate intrinsic value, Stock Options Outstanding at Beginning period	$ 15,624
Aggregate intrinsic value, Stock Options Outstanding at End period	1,859	$ 15,624
Aggregate intrinsic value, Vested and expected-to-vest at end of period	$ 1,375	$ 15,624
[1]	Less than 1

Share Capital - Summary of St55

Share Capital - Summary of Stock Option Activity (Details) (Parenthetical) - $ / shares	Dec. 31, 2017	Dec. 31, 2016
Equity [Abstract]
Per share	$ 0.01	$ 0.01

Share Capital - Schedule of Sto

Share Capital - Schedule of Stock Options Outstanding (Details) - $ / shares		12 Months Ended
		Dec. 31, 2017	Dec. 31, 2016
Stock options outstanding		6,224,479	2,614,916
Stock options exercisable		2,143,122	2,614,916
Exercise Price One [Member]
Exercise price		$ 0.28	$ 0.28
Stock options outstanding		1,167,693	1,167,693
Weighted average remaining contractual life		8 years	8 years
Stock options exercisable		1,167,693	1,167,693
Exercise Price Two [Member]
Exercise price		$ 1.05	$ 1.05
Stock options outstanding		2,003,187
Weighted average remaining contractual life		9 years 9 months	0 years
Stock options exercisable
Exercise Price Three [Member]
Exercise price		$ 1.29	$ 1.29
Stock options outstanding		1,087,627
Weighted average remaining contractual life		9 years 9 months	0 years
Stock options exercisable
Exercise Price Four [Member]
Exercise price		$ 1.02	$ 1.02
Stock options outstanding		990,543
Weighted average remaining contractual life		10 years	0 years
Stock options exercisable
Exercise Price Five [Member]
Exercise price	[1]
Stock options outstanding		975,429	1,447,223
Weighted average remaining contractual life		8 years 9 months	9 years 6 months
Stock options exercisable		975,429	1,447,223
[1]	Less than 1

Share Capital - Schedule of S57

Share Capital - Schedule of Stock Options Outstanding (Details) (Parenthetical) - $ / shares	Dec. 31, 2017	Dec. 31, 2016
Equity [Abstract]
Per share	$ 0.01	$ 0.01

Share Capital - Schedule of S58

Share Capital - Schedule of Stock Options Valuation Assumptions (Details)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Equity [Abstract]
Expected volatility	122.50%	77.30%
Risk-free interest	1.64%	0.60%
Dividend yield	0.00%	0.00%
Expected life of up to (years)	6 years 2 months 30 days	5 years

Basic and Diluted Net Loss Pe59

Basic and Diluted Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Earnings Per Share [Abstract]
Net loss attributable to shareholders of the company	$ 7,589	$ 9,662
Net loss attributable to shareholders of preferred shares	1,582	3,954
Net loss used in the calculation of basic net loss per share	$ 6,007	$ 5,709
Net loss per share	$ 0.18	$ 0.40
Weighted average number of common shares	32,682,401	14,293,737

Research and Development Expe60

Research and Development Expenses, Net - Schedule of Research and Development Expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Share-based compensation	$ 479	$ 676
Depreciation	21	10
Research and development expense	(1,100)	(901)
Research and Development Expense [Member]
Payroll and related expenses	634	491
Share-based compensation	1
Materials	266	155
Patents	66	75
Office and maintenance expenses	27	21
Rent	34	36
Professional services	174	253
Depreciation	12	7
Other	65	76
Less: Grants received from IIA	(179)	(213)
Research and development expense	$ 1,100	$ 901

General and Administrative Ex61

General and Administrative Expenses - Schedule of General and Administrative Expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Share-based compensation	$ 254	$ 675
Depreciation	21	10
Total	(4,167)	(8,734)
General and Administrative Expense [Member]
Payroll and related expenses	1,213	45
Share-based compensation	253	676
Professional services	1,217	528
Common shares issued for services		7,258
Travel	284	180
Marketing expenses	26
Office and maintenance expenses	121
Depreciation	9
Public and Investor Relations	515
Insurance	226
Governmental Fees	251
Other	52	47
Total	$ 4,167	$ 8,734

Finance Expenses, Net - Summary

Finance Expenses, Net - Summary of Finance Expenses, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Other Income and Expenses [Abstract]
Bank fees and interest	$ 1	$ 1
Change in fair value of derivative warrant liability	(285)	(262)
Financing loss on debt extinguishment	2,364
Exchange rate differences	5	(44)
Revaluation and interest on convertible loans	237	333
Financial expenses, net	$ 2,322	$ 28

Transactions and Balances wit63

Transactions and Balances with Interested and Related Parties - Schedule of Related Party Transaction and Balances (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Other accounts payable	$ 46
Total	46
Interested and Related Parties [Member]
Payroll and related expenses	851
Directors fees and insurance	463	58
Subcontracted work and consulting	67	253
Total	$ 1,381	$ 311

Taxes on Income (Details Narrat

Taxes on Income (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Corporate income tax rate	24.00%	25.00%
Israel Tax Authority [Member]
Net operating losses carried forward	$ 5,267
Israel Tax Authority [Member] | 2016 [Member]
Corporate income tax rate	25.00%
Israel Tax Authority [Member] | 2017 [Member]
Corporate income tax rate	24.00%
Israel Tax Authority [Member] | From 2018 [Member]
Corporate income tax rate	23.00%
US Tax Authority [Member]
Corporate income tax rate	35.00%
Net operating losses carried forward	$ 2,987
Operating loss carryforwards, expiration	2,035
Tax Act [Member] | From January 1, 2018 [Member]
Reduced federal tax rate	21.00%

Taxes on Income - Schedule of D

Taxes on Income - Schedule of Deferred Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Net operating loss carry-forward	$ 488,603	$ 481,052
Total deferred tax assets	117,265	120,263
Valuation allowance	(117,265)	(120,263)
Net deferred tax asset

Taxes on Income - Schedule of S

Taxes on Income - Schedule of Statutory Tax Rate and Effective Income Tax Rate (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Net loss as reported in the statements of operations	$ 7,589	$ 9,663
Statutory tax rate	24.00%	25.00%
Income Tax under statutory tax rate	$ 1,821	$ 2,416
Change in valuation allowance	(1,821)	(2,416)
Actual income tax

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Jan. 04, 2018	May 31, 2017	Mar. 30, 2018	Dec. 31, 2016
Series A Convertible Preferred Shares [Member]
Conversion of stock into shares		1,000		1,000
Subsequent Event [Member]
Buy back amount per patent	$ 1
Conversion of stock into shares			1,500,000
Subsequent Event [Member] | Series A Convertible Preferred Shares [Member]
Conversion of stock into shares			1,500
Subsequent Event [Member] | NIS [Member]
Monthly consultation fee	$ 40,000
Subsequent Event [Member] | Minimum [Member]
Investments	$ 2,000
Subsequent Event [Member] | CardioSert Ltd [Member]
Patent description	closing of the acquisition expected in April 2018, CardioSert’s issued U.S. patent and three patent applications pending worldwide will be added to Microbot’s patent portfolio which will then have a patent portfolio of 25 issued/allowed patents and 15 patent applications pending worldwide.
Initial payment	$ 50